Breaking News

Almac Adds CT Exec

By Gil Roth | December 12, 2012

Morris appointed to Clinical Technologies executive team

Charlie Morris has been named vice president of New Products and Services at the Almac Group’s Clinical Technologies business unit.  In this role, Mr. Morris will report directly to Jim Murphy, president of Almac Clinical Technologies, and will oversee the development of Almac’s IXRS technology and enhance the company’s metrics-based discipline to the software development process.

Mr. Morris brings extensive experience in systems management and development to Almac. His varied background includes service in the financial services, government, and medical technology sectors. He has served in all stages of the systems development process, from inception to development to execution, and has significant experience managing international personnel.

He joins Almac after spending more than ten years serving as the chief technology officer of Princeton Financial Systems (PFS), where he created and implemented multi-year IT strategic plans to grow and improve the PFS information technology infrastructure. Prior to his nearly two decades at PFS, Mr. Morris served as director of Applications Development at Telescan Ltd., building and implementing teleradiology systems. He began his career in military contracts where he developed flight simulation, anti-submarine warfare, and naval intelligence systems.

Mr. Murphy commented, “We are thrilled that Charlie Morris has joined Almac. He will be instrumental to the continued development of our IXRS integrated web and phone-based platform. Given his breadth of system development leadership experience, we are highly confident in his ability to align the New Products and Services department to support accelerated innovation of Almac’s technology. We welcome Charlie to Almac and know he will have a profound impact on the expansion of our technology offerings and client relationships.”
  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks

  • The Growing Realm of Real-World Data

    Kristin Brooks, Contract Pharma||November 8, 2016
    PPD's Evidera acquisition aims to help clients address the growing demand for evidence from regulators and payers

  • Mastering Immunotherapy Clinical Trials: Dosing and Response

    Mastering Immunotherapy Clinical Trials: Dosing and Response

    Kristin Brooks, Contract Pharma||August 1, 2016
    Andrew Zupnick of Novella Clinical provides insights into dosing and measuring response in immunotherapy clinical trials

  • CROs and Today’s  R&D Landscape

    CROs and Today’s R&D Landscape

    Kristin Brooks, Associate Editor, Contract Pharma||November 9, 2016
    John Lewis of ACRO discusses opportunities, challenges, and the future CRO

  • Choosing Oral Formulations for First-in-man Clinical Trials

    Choosing Oral Formulations for First-in-man Clinical Trials

    Jon Sutch, Senior Manager of Formulation Development, Patheon||October 11, 2016
    Early formulations should be simple, but selecting a simple formulation isn’t as easy as it seems

  • Robust Assay Designs

    Robust Assay Designs

    Tim Wright, Editor, Contract Pharma||October 11, 2016
    Easing the transition from preclinical to clinical research